For rheumatologists treating psoriatic arthritis (PsA), choosing a therapy is not only about efficacy and safety. Formulary position, prior authorization, step therapy, biosimilar availability, copay assistance and route of administration can significantly influence whether a patient can actually start and remain on treatment.
See what is happening inside companies and what it means for customers and your business. Download Sample: https://www.towardshealthcare.com/download-sample/5122
The leading options include Humira and its adalimumab biosimilars, Enbrel, Cosentyx, Tremfya, Skyrizi, Taltz, Otezla and Rinvoq. However, the most affordable option for one patient may be poorly covered for another because payer formularies differ substantially. The American Academy of Dermatology lists several of these agents as FDA-approved biologics for PsA.
Humira and Adalimumab Biosimilars: Strongest Cost-Competition Opportunity
Humira (adalimumab) has historically been one of the most widely used TNF inhibitors for PsA. Its biggest advantage from an affordability perspective is the large number of FDA-approved biosimilars now competing with the reference product.
FDA records include Simlandi, Yuflyma, Idacio and other adalimumab biosimilars.
This competition has materially changed coverage. According to the HHS Office of Inspector General, 96% of Medicare Part D prescription-drug plans and 88% of Medicare Advantage prescription-drug plans covered at least one Humira biosimilar in 2025, compared with 65% and 52%, respectively, in 2024.
Why consider Humira or its biosimilars?
Pros
- Large biosimilar ecosystem
- Strong payer familiarity
- FDA-approved options across multiple manufacturers
- Potentially lower acquisition costs
- Broad PsA experience
- Increasing Medicare formulary availability
- Biosimilars can provide additional competition and potentially lower costs.
Cons
- Coverage varies considerably between individual plans
- Prior authorization and step therapy can still apply
- Some plans may prefer a specific adalimumab biosimilar
- Humira itself may have less favorable formulary positioning than a preferred biosimilar
For physicians prioritizing coverage flexibility and lower-cost biologic options, adalimumab biosimilars deserve particular attention.
Enbrel: Established Coverage and Payer Familiarity
Enbrel (etanercept) is another established TNF inhibitor with a long history in inflammatory arthritis.
Its advantage is not necessarily the lowest price, but longstanding payer and physician familiarity.
Recent U.S. formularies demonstrate this. For example, the 2026 KPP formulary lists Enbrel as a preferred PsA option, alongside several other biologics.
Why consider Enbrel?
Pros
- Long clinical experience
- Established payer relationships
- Frequently appears as a preferred biologic
- FDA-approved for PsA
- Familiar administration and monitoring pathway
Cons
- No equivalent level of biosimilar competition to adalimumab
- Coverage can still require prior authorization
- Some newer IL-17 and IL-23 therapies may be preferred depending on the plan
- Patient copay can remain significant
Enbrel can be attractive when a patient’s insurance places it in a preferred tier with manageable cost sharing.
Cosentyx: Strong Coverage Support and Patient Assistance
Cosentyx (secukinumab) is an IL-17A inhibitor approved for PsA and has become an important alternative to TNF inhibitors.
Its manufacturer, Novartis, provides a substantial access program. As of July 2026, the listed wholesale price for Cosentyx self-injection is $8,492.03 per month, although the manufacturer notes that insured patients generally pay less than the list price.
Novartis reports that 84% of eligible patients using its copay program paid $0 out of pocket in 2024. Eligible patients may also receive up to two years of free Cosentyx through its bridge program if insurance coverage is unavailable.
Why consider Cosentyx?
Pros
- FDA-approved for PsA
- Strong specialty-pharmacy infrastructure
- Manufacturer copay support
- Bridge program for eligible patients
- Appears as a preferred PsA option on some 2026 formularies
- Multiple dosing and administration options
Cons
- Very high list price
- Coverage varies by insurer
- Prior authorization may apply
- Patients without qualifying commercial insurance may not receive the same assistance
Cosentyx can therefore be attractive when clinical fit and manufacturer affordability programs align with payer coverage.
Tremfya: Growing IL-23 Option
Tremfya (guselkumab) is an IL-23 inhibitor approved for PsA and is increasingly important in treatment selection.
Its access advantage comes from increasing formulary presence. For example, the 2026 KPP formulary lists Tremfya as a preferred PsA option, while another 2026 specialty formulary also lists it among preferred therapies.
Why consider Tremfya?
Pros
- FDA-approved for PsA
- Preferred on some U.S. formularies
- Longer dosing intervals can reduce administration burden
- Strong specialty-drug infrastructure
- Useful option when payer coverage favors IL-23 therapy
Cons
- List price remains high
- Coverage is plan-specific
- Prior authorization or step therapy may apply
- Limited biosimilar price competition compared with adalimumab
Tremfya becomes particularly interesting when a patient’s plan prefers an IL-23 therapy and the clinical profile is appropriate.
Skyrizi: Strong Biologic Option With Variable Coverage
Skyrizi (risankizumab) is another IL-23 inhibitor approved for PsA.
It is included among FDA-approved PsA biologics and appears as a preferred option on several 2026 formularies.
Why consider Skyrizi?
Pros
- FDA-approved for PsA
- Preferred option on some formularies
- Longer maintenance dosing can reduce treatment burden
- Strong specialty-pharmacy support
- Broad immunology portfolio
Cons
- High branded-biologic cost
- Coverage varies by plan
- Prior authorization may be required
- Limited biosimilar competition
For patients whose insurance prefers Skyrizi, it can provide a strong balance between treatment convenience and coverage.
Contact us for more: https://www.towardshealthcare.com/contact-us
Taltz: Established IL-17 Option
Taltz (ixekizumab) is an IL-17A inhibitor approved for PsA.
It has substantial clinical experience and is included among FDA-approved biologics for PsA.
Why consider Taltz?
Pros
- Established PsA treatment
- FDA-approved for PsA
- Preferred on some formularies
- Strong specialty-pharmacy infrastructure
- Useful alternative when TNF or other mechanisms are unsuitable
Cons
- High branded-drug cost
- Coverage varies substantially
- Prior authorization may apply
- Usually lacks the cost advantage created by large biosimilar competition
Taltz can be particularly practical when the patient’s formulary places it among preferred IL-17 options.
Otezla: Oral Option With a Different Access Profile
Otezla (apremilast) differs from the biologics above because it is an oral small-molecule therapy.
Its administration can make it attractive for patients who prefer to avoid injections or infusions.
Some 2026 formularies list Otezla as a preferred PsA option, including the KPP and Oscar 2026 formularies.
Why consider Otezla?
Pros
- Oral administration
- No injection training
- No biologic infusion requirement
- Preferred on some formularies
- Potentially simpler logistics for certain patients
Cons
- Coverage still varies
- May require prior authorization
- Not necessarily the lowest-cost option
- Clinical suitability differs from biologic therapy
- Patient-specific disease severity and treatment goals remain important
Otezla can be particularly useful when oral administration and formulary positioning are important considerations.
How Do the Leading PsA Brands Compare on Cost and Coverage?
| Brand / option | Drug class | Cost-access advantage | Coverage signal | Main limitation |
|---|---|---|---|---|
| Humira biosimilars | TNF inhibitor | Strong biosimilar competition | 96% of Part D plans covered ≥1 biosimilar in 2025 | Plan-specific preferred product |
| Enbrel | TNF inhibitor | Established payer relationships | Preferred on some 2026 formularies | Limited biosimilar competition |
| Cosentyx | IL-17A | Copay + bridge programs | Preferred on some formularies | High list price |
| Tremfya | IL-23 | Longer dosing intervals | Preferred on some formularies | High branded cost |
| Skyrizi | IL-23 | Longer maintenance dosing | Preferred on some formularies | High branded cost |
| Taltz | IL-17A | Manufacturer access support | Preferred on some formularies | High branded cost |
| Otezla | PDE4 inhibitor | Oral administration | Preferred on some formularies | Clinical suitability varies |
| Rinvoq | JAK inhibitor | Manufacturer assistance may apply | Preferred on some formularies | Safety and payer requirements |
Importantly, formulary placement is not universal. One 2026 formulary, for example, lists Enbrel, Humira biosimilars, Otezla, Rinvoq, Skyrizi and Tremfya as preferred, while placing Cosentyx and several other therapies in a non-preferred category. Another plan has Cosentyx, Enbrel, Humira, Otezla, Rinvoq, Skyrizi and Tremfya among preferred PsA products.
This illustrates why the “best” cost-and-coverage choice must be determined at the individual payer and patient level.
Who Are the Actual Buyers?
The PsA access ecosystem includes:
- Patients: ultimately bear premiums, deductibles and copays
- Rheumatologists: major clinical decision-makers
- Dermatologists: important when psoriasis is prominent
- Commercial insurers: determine formulary placement
- Medicare Part D plans: important for older patients
- Medicare Advantage plans: influence biologic access
- Pharmacy benefit managers: influence formulary and utilization management
- Specialty pharmacies: handle dispensing and patient support
- Hospitals and health systems: relevant for infusion-based therapies
Medicare explains that Part D formularies can include both brand biologics and biosimilars, but individual plans determine which products they offer.
Where Are the Biggest Affordability Opportunities?
The U.S. is particularly important because PsA biologics frequently involve complex insurance coverage, specialty-pharmacy distribution and prior authorization.
The biggest affordability opportunity is currently associated with biosimilar competition, especially adalimumab.
The HHS OIG found that coverage of Humira biosimilars expanded sharply from 2024 to 2025:
- 96% of Medicare Part D plans covered at least one Humira biosimilar in 2025.
- 88% of Medicare Advantage prescription-drug plans covered at least one.
- In 2024, the corresponding figures were 65% and 52%.
- 99% of formularies covering Humira and biosimilars placed them on the same cost-sharing tier.
This demonstrates that biosimilar availability does not automatically mean lower patient cost. Formulary design and benefit structure remain critical.
What Makes a PsA Medicine More Affordable?
Cost is influenced by much more than the manufacturer’s list price.
Key factors include:
- Formulary tier
- Prior authorization
- Step therapy
- Deductible
- Coinsurance
- Copay
- Manufacturer assistance
- Biosimilar availability
- Specialty-pharmacy requirements
- Route of administration
- Infusion versus self-injection
- Patient eligibility for assistance programs
FDA specifically notes that biosimilars may cost less and may be covered by more insurers, but actual patient savings depend on insurance and benefit design.
What Should Rheumatologists Focus On?
For cost-conscious PsA treatment decisions, clinicians should evaluate:
- Clinical appropriateness first
- Patient insurance and formulary
- Preferred biologic status
- Biosimilar alternatives
- Prior-authorization requirements
- Step-therapy requirements
- Patient out-of-pocket exposure
- Manufacturer assistance eligibility
- Specialty-pharmacy requirements
- Administration burden
- Continuity of coverage
A lower list price does not necessarily produce the lowest patient cost, and a highly effective biologic may become practically inaccessible if the patient’s insurer requires multiple steps before approval.
What Towards Healthcare Offers You?
Towards Healthcare Research & Consulting can help pharmaceutical companies, investors, payers and healthcare organizations track:
- PsA drug pricing and affordability
- Competitor drug portfolios
- Biosimilar launches
- Formulary positioning
- Insurance coverage
- Prior-authorization trends
- Patient assistance programs
- Sales and revenue
- Prescriber and buyer intelligence
- Specialty-pharmacy dynamics
- Regional opportunities
- Competitive investments and strategy
The objective is to connect drug economics, payer coverage, patient affordability and competitive intelligence to identify which PsA therapies have the strongest access position and where coverage barriers remain.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium